ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
향후 몇 년동안 레보도파 유발성 이상운동증(LID) 시장은 이 질환에 대한 인식이 높아지고 전 세계 의료비 지출이 증가함에 따라 변화할 것으로 예상됩니다.
기업과 연구기관들은 레보도파 유발성 이상운동증(LID) 연구 개발에 영향을 미칠 수 있는 과제를 평가하고 기회를 모색하기 위해 노력하고 있습니다. 개발 중인 치료법은 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞추었습니다. 주요 기업들이 레보도파 유발성 이상운동증(LID) 치료제 개발에 참여하고 있습니다. 새로운 치료법의 등장은 레보도파 유발성 이상운동증(LID) 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 레보도파 유발성 이상운동증(LID) 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 의료 미충족 수요 등을 제공합니다.
목차
제1장 주요 인사이트
제2장 레보도파유발성 이상운동증(LID) 주요 요약
제3장 레보도파유발성 이상운동증(LID) 경쟁 정보 분석
제4장 레보도파유발성 이상운동증(LID) : 시장 개요
제5장 레보도파유발성 이상운동증(LID) : 질환 배경과 개요
서론
징후와 증상
병태생리학
위험 요인
진단
제6장 환자 동향
제7장 레보도파유발성 이상운동증(LID) 역학과 환자 인구
역학 주요 조사 결과
전제와 근거 : 주요 7개국
역학 시나리오 : 주요 7개국
미국
유럽 5개국
일본
제8장 치료 알고리즘, 현재의 치료 및 의료 행위
제9장 미충족 요구
제10장 레보도파유발성 이상운동증(LID) 치료의 주요 평가 항목
제11장 출시 제품
제12장 새로운 치료법
제13장 레보도파유발성 이상운동증(LID) : 주요 7개국 시장 분석
제14장 속성 분석
제15장 주요 7개국 : 시장 전망
미국 : 시장 규모
유럽 5개국 : 시장 규모와 전망
독일 시장 규모
프랑스 시장 규모
이탈리아 시장 규모
스페인 시장 규모
영국 시장 규모
일본 시장 규모
제16장 레보도파유발성 이상운동증(LID) 접근 및 상환 개요
제17장 KOL(Key Opinion Leader)의 견해
제18장 시장 성장 촉진요인
제19장 시장 장벽
제20장 부록
제21장 DelveInsight의 서비스 내용
제22장 면책사항
제23장 DelveInsight에 대해
LSH
영문 목차
영문목차
DelveInsight's "Levodopa-Induced Dyskinesia (LID) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Levodopa-Induced Dyskinesia (LID), historical and forecasted epidemiology as well as the Levodopa-Induced Dyskinesia (LID) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Levodopa-Induced Dyskinesia (LID) market report provides current treatment practices, emerging drugs, Levodopa-Induced Dyskinesia (LID) market share of the individual therapies, current and forecasted Levodopa-Induced Dyskinesia (LID) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Levodopa-Induced Dyskinesia (LID) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2020-2034
Levodopa-Induced Dyskinesia (LID) Disease Understanding and Treatment Algorithm
The DelveInsight Levodopa-Induced Dyskinesia (LID) market report gives a thorough understanding of the Levodopa-Induced Dyskinesia (LID) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Levodopa-Induced Dyskinesia (LID).
Treatment
It covers the details of conventional and current medical therapies available in the Levodopa-Induced Dyskinesia (LID) market for the treatment of the condition. It also provides Levodopa-Induced Dyskinesia (LID) treatment algorithms and guidelines in the United States, Europe, and Japan.
Levodopa-Induced Dyskinesia (LID) Epidemiology
The Levodopa-Induced Dyskinesia (LID) epidemiology division provide insights about historical and current Levodopa-Induced Dyskinesia (LID) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Levodopa-Induced Dyskinesia (LID) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
Country Wise-Levodopa-Induced Dyskinesia (LID) Epidemiology
The epidemiology segment also provides the Levodopa-Induced Dyskinesia (LID) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Levodopa-Induced Dyskinesia (LID) Drug Chapters
Drug chapter segment of the Levodopa-Induced Dyskinesia (LID) report encloses the detailed analysis of Levodopa-Induced Dyskinesia (LID) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Levodopa-Induced Dyskinesia (LID) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Levodopa-Induced Dyskinesia (LID) treatment.
Levodopa-Induced Dyskinesia (LID) Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Levodopa-Induced Dyskinesia (LID) treatment.
Levodopa-Induced Dyskinesia (LID) Market Outlook
The Levodopa-Induced Dyskinesia (LID) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Levodopa-Induced Dyskinesia (LID) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Levodopa-Induced Dyskinesia (LID) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Levodopa-Induced Dyskinesia (LID) market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Levodopa-Induced Dyskinesia (LID) market in 7MM.
The United States Market Outlook
This section provides the total Levodopa-Induced Dyskinesia (LID) market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Levodopa-Induced Dyskinesia (LID) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Levodopa-Induced Dyskinesia (LID) market size and market size by therapies in Japan is also mentioned.
Levodopa-Induced Dyskinesia (LID) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Levodopa-Induced Dyskinesia (LID) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Levodopa-Induced Dyskinesia (LID) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Levodopa-Induced Dyskinesia (LID) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Levodopa-Induced Dyskinesia (LID) key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Levodopa-Induced Dyskinesia (LID) emerging therapies.
Reimbursement Scenario in Levodopa-Induced Dyskinesia (LID)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Levodopa-Induced Dyskinesia (LID) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Levodopa-Induced Dyskinesia (LID) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Levodopa-Induced Dyskinesia (LID) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report:
The report covers the descriptive overview of Levodopa-Induced Dyskinesia (LID), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Levodopa-Induced Dyskinesia (LID) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Levodopa-Induced Dyskinesia (LID) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Levodopa-Induced Dyskinesia (LID) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Levodopa-Induced Dyskinesia (LID) market
Report Highlights:
In the coming years, Levodopa-Induced Dyskinesia (LID) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Levodopa-Induced Dyskinesia (LID) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Levodopa-Induced Dyskinesia (LID). Launch of emerging therapies will significantly impact the Levodopa-Induced Dyskinesia (LID) market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Levodopa-Induced Dyskinesia (LID)
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
What was the Levodopa-Induced Dyskinesia (LID) market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Levodopa-Induced Dyskinesia (LID) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Levodopa-Induced Dyskinesia (LID) market size during the forecast period (2024-2034)?
At what CAGR, the Levodopa-Induced Dyskinesia (LID) market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Levodopa-Induced Dyskinesia (LID) market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Levodopa-Induced Dyskinesia (LID) market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
What is the disease risk, burden and unmet needs of the Levodopa-Induced Dyskinesia (LID)?
What is the historical Levodopa-Induced Dyskinesia (LID) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Levodopa-Induced Dyskinesia (LID) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Levodopa-Induced Dyskinesia (LID)?
Out of all 7MM countries, which country would have the highest prevalent population of Levodopa-Induced Dyskinesia (LID) during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Levodopa-Induced Dyskinesia (LID) treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Levodopa-Induced Dyskinesia (LID) in the USA, Europe, and Japan?
What are the Levodopa-Induced Dyskinesia (LID) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Levodopa-Induced Dyskinesia (LID)?
How many therapies are developed by each company for Levodopa-Induced Dyskinesia (LID) treatment?
How many are emerging therapies in mid-stage, and late stage of development for Levodopa-Induced Dyskinesia (LID) treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Levodopa-Induced Dyskinesia (LID) therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Levodopa-Induced Dyskinesia (LID) and their status?
What are the key designations that have been granted for the emerging therapies for Levodopa-Induced Dyskinesia (LID)?
What are the global historical and forecasted market of Levodopa-Induced Dyskinesia (LID)?
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the Levodopa-Induced Dyskinesia (LID) market
To understand the future market competition in the Levodopa-Induced Dyskinesia (LID) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Levodopa-Induced Dyskinesia (LID) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Levodopa-Induced Dyskinesia (LID) market
To understand the future market competition in the Levodopa-Induced Dyskinesia (LID) market
Table of Contents
1. Key Insights
2. Executive Summary of Levodopa-Induced Dyskinesia (LID)
3. Competitive Intelligence Analysis for Levodopa-Induced Dyskinesia (LID)
4. Levodopa-Induced Dyskinesia (LID): Market Overview at a Glance
4.1. Levodopa-Induced Dyskinesia (LID) Total Market Share (%) Distribution in 2020
4.2. Levodopa-Induced Dyskinesia (LID) Total Market Share (%) Distribution in 2034
5. Levodopa-Induced Dyskinesia (LID): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Levodopa-Induced Dyskinesia (LID) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
7.4.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Germany (2020-2034)
7.5.2. France Epidemiology
7.5.2.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in France (2020-2034)
7.5.3. Italy Epidemiology
7.5.3.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Italy (2020-2034)
7.5.4. Spain Epidemiology
7.5.4.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Spain (2020-2034)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in the United Kingdom (2020-2034)
7.5.6. Japan Epidemiology
7.5.6.1. Levodopa-Induced Dyskinesia (LID) Epidemiology Scenario in Japan (2020-2034)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Levodopa-Induced Dyskinesia (LID) Treatment and Management
